US 12,201,625 B2
Single nucleotide polymorphic alleles of human DP-2 gene for detection of susceptibility to hair growth inhibition by PGD2
George Cotsarelis, Berwyn, PA (US); Ying Zheng, West Chester, PA (US); Jen-Chih Hsieh, South Setauket, NY (US); David Collins, Philadelphia, PA (US); and Joan O'Brien, Merion Station, PA (US)
Assigned to The Trustees of the University of Pennsylvania, Philadelphia, PA (US)
Appl. No. 15/748,641
Filed by THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, Philadelphia, PA (US)
PCT Filed Jul. 28, 2016, PCT No. PCT/US2016/044457
§ 371(c)(1), (2) Date Jan. 29, 2018,
PCT Pub. No. WO2017/019858, PCT Pub. Date Feb. 2, 2017.
Claims priority of provisional application 62/198,888, filed on Jul. 30, 2015.
Prior Publication US 2020/0078351 A1, Mar. 12, 2020
Int. Cl. A61K 31/473 (2006.01); A61K 9/00 (2006.01); A61K 31/192 (2006.01); A61K 31/404 (2006.01); A61K 31/437 (2006.01); A61K 31/47 (2006.01); A61K 31/506 (2006.01); A61P 17/14 (2006.01); C12Q 1/6883 (2018.01)
CPC A61K 31/473 (2013.01) [A61K 9/0014 (2013.01); A61K 9/0053 (2013.01); A61K 31/192 (2013.01); A61K 31/404 (2013.01); A61K 31/437 (2013.01); A61K 31/47 (2013.01); A61K 31/506 (2013.01); A61P 17/14 (2018.01); C12Q 1/6883 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01)] 9 Claims
OG exemplary drawing
 
1. A method of treatment of androgenetic alopecia, baldness or hair loss in a subject that is identified to be likely to be responsive to administration of a DP-2 antagonist that is a selective DP-2 antagonist with respect to DP-1 to stimulate hair growth, comprising:
(i) genotyping single nucleotide polymorphic loci within or flanking the DP-2 gene in a genomic DNA sample obtained from the subject, wherein single nucleotide polymorphic loci rs545659, rs634681, and rs7167 are genotyped;
(ii) determining whether the subject is likely to be responsive to administration of the DP-2 antagonist, based on the genotype detected at each of the loci rs545659, rs634681, and rs7167, wherein the subject is likely to be responsive to administration of the DP-2 antagonist if the subject carries minor alleles for each of the single nucleotide polymorphic loci rs545659, rs634681, and rs7167; and
(iii) administering the DP-2 antagonist to the subject who carries minor alleles for each of the single nucleotide polymorphic loci rs545659, rs634681, and rs7167.